# SPINK2

## Overview
SPINK2 is a gene that encodes the serine peptidase inhibitor Kazal type 2, a protein that functions as a serine protease inhibitor. This protein is primarily involved in the regulation of protease activities during spermatogenesis, playing a crucial role in the development and maturation of sperm cells. The SPINK2 protein is characterized by a Kazal-type domain, which is essential for its inhibitory function, particularly against proteases such as trypsin and acrosin. This domain includes structural features like disulfide bonds that confer stability and specificity to the protein's inhibitory activity (Chen2009Identification). Beyond its role in reproductive biology, SPINK2 is also implicated in various pathological conditions, including acute myeloid leukemia and certain cancers, where it influences cell proliferation, migration, and response to treatment (Pitts2023SPINK2; Guo2024RARRES1). The gene's expression and mutations have significant clinical implications, making it a potential target for therapeutic interventions in both oncology and reproductive medicine (Kherraf2017SPINK2).

## Structure
The SPINK2 protein is characterized by a Kazal-type domain, which is crucial for its function as a serine proteinase inhibitor. This domain includes six cysteine residues that form three disulfide bonds, contributing significantly to the protein's structural stability (Chen2009Identification). The secondary structure of SPINK2 consists of approximately 50% random coil, 10% alpha-helix, and 40% beta-sheet conformation, as determined by circular dichroism spectroscopy (Chen2009Identification). The protein features a short three-stranded antiparallel β-sheet and an α-helix, with a β-bulge at Ile 57 (Chen2009Identification).

The tertiary structure of SPINK2 was elucidated using NMR spectroscopy, revealing a stable conformation due to the disulfide bonds. The root-mean-square deviation (RMSD) values for the backbone atoms were 1.89 Å, indicating some flexibility, particularly in the N-terminal region, while the well-defined region (residues Pro 28 - Cys 62) showed lower RMSD values, suggesting a more stable structure (Chen2009Identification). The protein's structure was refined using the OPLS force field, resulting in 15 structures with the lowest total energies (Chen2009Identification). Despite sharing less than 50% sequence identity with other Kazal-type inhibitors, SPINK2 maintains similar disulfide-bridge patterns and secondary structural elements (Chen2009Identification).

## Function
SPINK2, a serine protease inhibitor, plays a critical role in spermatogenesis by regulating protease activities within sperm cells. It is primarily active in the acrosomal vesicle of round spermatids and remains present in mature spermatozoa. SPINK2 functions to neutralize acrosomal proteases, such as acrosin, preventing their premature activation during cellular transit through compartments like the endoplasmic reticulum and Golgi apparatus, which could otherwise lead to autoactivation due to their pH levels (Kherraf2017SPINK2).

The protein is essential for acrosome biogenesis, as its absence disrupts the fusion of proacrosomal vesicles and leads to Golgi apparatus fragmentation, ultimately causing a blockade in spermatid differentiation at the round-spermatid stage (Kherraf2017SPINK2). This disruption can result in severe infertility phenotypes, such as azoospermia, characterized by the absence of mature sperm (Kherraf2017SPINK2).

SPINK2 also exhibits trypsin-inhibitory activity, which is crucial for its function as a serine proteinase inhibitor. Its structure, characterized by a Kazal domain with disulfide bridges, supports its role in inhibiting serine proteinases like trypsin and acrosin (Chen2009Identification).

## Clinical Significance
Mutations and alterations in the SPINK2 gene have significant clinical implications, particularly in the context of acute myeloid leukemia (AML) and male infertility. In AML, SPINK2 is identified as an independent adverse prognostic marker. High expression levels of SPINK2 are associated with poor survival outcomes, therapy resistance, and increased relapse rates. It is particularly linked with AML cases having NPM1 mutations and intermediate risk by cytogenetics. SPINK2 expression can refine prognostic stratification and is potentially involved in regulating ferroptosis and immune response, which could represent novel therapeutic vulnerabilities in AML (Pitts2023SPINK2).

In the realm of male infertility, SPINK2 mutations can lead to severe reproductive issues. Homozygous mutations in SPINK2 result in azoospermia, while heterozygous mutations can cause oligozoospermia, indicating that SPINK2 haploinsufficiency affects sperm production. The absence of SPINK2 disrupts acrosome formation and activates a self-degradation pathway, leading to infertility due to disrupted spermatogenesis (Kherraf2017SPINK2). These findings underscore the importance of SPINK2 in both hematological malignancies and reproductive health, highlighting its potential as a target for therapeutic interventions.

## Interactions
SPINK2, a serine protease inhibitor, is known to interact with various proteins, playing a significant role in modulating proteolytic activity. In the context of testicular carcinoma cells, SPINK2 interacts with Tazarotene-induced gene 1 (TIG1). This interaction has been shown to inhibit cellular invasion and migration by downregulating the activity of urokinase-type plasminogen activator (uPA), a key component in epithelial-mesenchymal transition (EMT) processes. The coexpression of SPINK2 and TIG1 enhances the suppression of cell invasion and migration, while silencing SPINK2 reverses these effects. This suggests that SPINK2 is crucial for TIG1-mediated regulation of the uPA system and EMT processes (Shyu2019TazaroteneInduced).

SPINK2 also interacts with RARRES1 in hepatocellular carcinoma (HCC) cells. This interaction is significant in modulating cancer progression and response to treatment. SPINK2 overexpression decreases HCC cell proliferation and migration while increasing sensitivity to lenvatinib, a cancer treatment drug. Conversely, SPINK2 knockdown has the opposite effects, indicating its role in enhancing the therapeutic efficacy of lenvatinib through its interaction with RARRES1 (Guo2024RARRES1).


## References


[1. (Pitts2023SPINK2) Herbert Augustus Pitts, Chi-Keung Cheng, Joyce Sin Cheung, Murphy Ka-Hei Sun, Yuk-Lin Yung, Hoi-Yun Chan, Raymond S. M. Wong, Sze-Fai Yip, Ka-Ngai Lau, Wai Shan Wong, Radha Raghupathy, Natalie P. H. Chan, and Margaret H. L. Ng. Spink2 protein expression is an independent adverse prognostic marker in aml and is potentially implicated in the regulation of ferroptosis and immune response. International Journal of Molecular Sciences, 24(11):9696, June 2023. URL: http://dx.doi.org/10.3390/ijms24119696, doi:10.3390/ijms24119696. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24119696)

[2. (Chen2009Identification) Ting Chen, Tian‐Ren Lee, Wei‐Guang Liang, Wun‐Shaing Wayne Chang, and Ping‐Chiang Lyu. Identification of trypsin‐inhibitory site and structure determination of human spink2 serine proteinase inhibitor. Proteins: Structure, Function, and Bioinformatics, 77(1):209–219, May 2009. URL: http://dx.doi.org/10.1002/prot.22432, doi:10.1002/prot.22432. This article has 19 citations.](https://doi.org/10.1002/prot.22432)

[3. (Kherraf2017SPINK2) Zine‐Eddine Kherraf, Marie Christou‐Kent, Thomas Karaouzene, Amir Amiri‐Yekta, Guillaume Martinez, Alexandra S Vargas, Emeline Lambert, Christelle Borel, Béatrice Dorphin, Isabelle Aknin‐Seifer, Michael J Mitchell, Catherine Metzler‐Guillemain, Jessica Escoffier, Serge Nef, Mariane Grepillat, Nicolas Thierry‐Mieg, Véronique Satre, Marc Bailly, Florence Boitrelle, Karin Pernet‐Gallay, Sylviane Hennebicq, Julien Fauré, Serge P Bottari, Charles Coutton, Pierre F Ray, and Christophe Arnoult. <scp>spink</scp>2 deficiency causes infertility by inducing sperm defects in heterozygotes and azoospermia in homozygotes. EMBO Molecular Medicine, 9(8):1132–1149, May 2017. URL: http://dx.doi.org/10.15252/emmm.201607461, doi:10.15252/emmm.201607461. This article has 91 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.15252/emmm.201607461)

[4. (Shyu2019TazaroteneInduced) Rong-Yaun Shyu, Chun-Hua Wang, Chang-Chieh Wu, Lu-Kai Wang, Mao-Liang Chen, Chan-Yen Kuo, Ming-Cheng Lee, Yi-Ying Lin, and Fu-Ming Tsai. Tazarotene-induced gene 1 (tig1) interacts with serine protease inhibitor kazal-type 2 (spink2) to inhibit cellular invasion of testicular carcinoma cells. BioMed Research International, 2019:1–10, November 2019. URL: http://dx.doi.org/10.1155/2019/6171065, doi:10.1155/2019/6171065. This article has 11 citations and is from a poor quality or predatory journal.](https://doi.org/10.1155/2019/6171065)

[5. (Guo2024RARRES1) Yarong Guo, Bao Chai, Hezhao Zhang, Xinhao Chai, Yan Chen, Jun Xu, Liwei Qin, and Yuting Chai. Rarres1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with spink2. Biology Direct, February 2024. URL: http://dx.doi.org/10.1186/s13062-024-00459-0, doi:10.1186/s13062-024-00459-0. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13062-024-00459-0)